The detection and clinical application of serologic biomarkers for liver fibrosis, the present and future perspectives
10.3760/cma.j.issn.1009-9158.2014.02.005
- VernacularTitle:肝脏纤维化的血清学标志物检测的现状和展望
- Author:
Lisong SHEN
;
Yunlan ZHOU
- Publication Type:Journal Article
- Keywords:
Liver cirrhosis;
Extracellular matrix;
Biological markers
- From:
Chinese Journal of Laboratory Medicine
2014;37(2):93-95
- CountryChina
- Language:Chinese
-
Abstract:
Hepatic fibrosis is the final common pathway for liver injury caused by various chronic liver diseases.Noninvasive assessments of liver fibrosis are valuable in clinical use since they are easy to apply and monitor disease progression.Serologic biomarkers for liver fibrosis consist of direct markers which reflect ECM turnover and indirect markers which show liver function of synthesis,metabolism and reservation.A number of assessment models can identify significant fibrosis and cirrhosis,and avoid unnecessary liver biopsy.They can be used for disease staging,prognosis prediction,and treatment surveillance.Variation of analytical performances exists among diverse analyzers and assays.The standardization of these tests will enhance their comparability.Large scale and multicenter clinical verification studies are needed for the clinical utility of these assessment models based on Chinese population of chronic hepatic diseases.
